![]() |

![]() |
Create Name: | |
Description: |
![]() |
Save what matters to you |
{{ loginError }} |
Sign in with your RGD account |
Create New Account | Recover Password |
Analyze GeneStrainQTL List |
![]() Gene Annotator (Functional Annotation) unavailable |
![]() Gene Annotator (Annotation Distribution) unavailable |
![]() Variant Visualizer (Genomic Variants) unavailble Variant Visualizer (Genomic Variants) unavailable |
Gene Annotator (Functional Annotation) |
Gene Annotator (Annotation Distribution) |
Variant Visualizer (Genomic Variants) |
![]() InterViewer (Protein-Protein Interactions) unavailable |
![]() Gviewer (Genome Viewer) unavailable |
![]() Variant Visualizer (Damaging Variants) unavailble Variant Visualizer (Damaging Variants) unavailable |
InterViewer (Protein-Protein Interactions) |
GViewer (Genome Viewer) |
Variant Visualizer (Damaging Variants) |
![]() Gene Annotator (Annotation Comparison) unavailable |
![]() OLGA (Gene List Generator) unavailable |
![]() |
Gene Annotator (Annotation Comparison) |
OLGA (Gene List Generator) |
Excel (Download) |
![]() MOET (Multi-Ontology Enrichement) unavailable |
![]() GOLF (Gene-Ortholog Location Finder) unavailable |
|
MOET (Multi-Ontology Enrichement) |
GOLF (Gene-Ortholog Location Finder) |
![]() Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (+)-schisandrin B | multiple interactions | ISO | RGD:1305387 | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of HSDL2 mRNA] | CTD | PMID:31150632 | (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HSDL2 mRNA | CTD | PMID:22079256 | 17beta-estradiol | multiple interactions | EXP | | 6480464 | [Estradiol co-treated with NADP] binds to HSDL2 protein | CTD | PMID:25526675 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:1551494 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of HSDL2 mRNA | CTD | PMID:19465110 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of HSDL2 mRNA | CTD | PMID:20106945, PMID:21632981 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1305387 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of HSDL2 mRNA | CTD | PMID:21215274 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of HSDL2 mRNA | CTD | PMID:22298810 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1551494 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of HSDL2 mRNA | CTD | PMID:19770486 | 3,3',4,4',5-pentachlorobiphenyl | increases expression | EXP | | 6480464 | 3 more ... | CTD | PMID:19692669 | 4-hydroxyphenyl retinamide | decreases expression | ISO | RGD:1551494 | 6480464 | Fenretinide results in decreased expression of HSDL2 mRNA | CTD | PMID:28973697 | 5-aza-2'-deoxycytidine | decreases expression | EXP | | 6480464 | Decitabine results in decreased expression of HSDL2 mRNA | CTD | PMID:19194470 | 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole | affects expression | ISO | RGD:1305387 | 6480464 | Omeprazole affects the expression of HSDL2 mRNA | CTD | PMID:19483382 | 6-propyl-2-thiouracil | affects expression | ISO | RGD:1305387 | 6480464 | Propylthiouracil affects the expression of HSDL2 mRNA | CTD | PMID:19483382 | aflatoxin B1 | increases expression | ISO | RGD:1551494 | 6480464 | Aflatoxin B1 results in increased expression of HSDL2 mRNA | CTD | PMID:19770486 | all-trans-retinoic acid | increases expression | EXP | | 6480464 | Tretinoin results in increased expression of HSDL2 mRNA | CTD | PMID:21934132 | amiodarone | affects expression | ISO | RGD:1305387 | 6480464 | Amiodarone affects the expression of HSDL2 mRNA | CTD | PMID:19483382 | azathioprine | decreases expression | EXP | | 6480464 | Azathioprine results in decreased expression of HSDL2 mRNA | CTD | PMID:22623647 | benzbromarone | affects expression | ISO | RGD:1305387 | 6480464 | Benzbromarone affects the expression of HSDL2 mRNA | CTD | PMID:19483382 | benzo[a]pyrene | increases expression | ISO | RGD:1551494 | 6480464 | Benzo(a)pyrene results in increased expression of HSDL2 mRNA | CTD | PMID:19770486 | bis(2-ethylhexyl) phthalate | increases expression | ISO | RGD:1551494 | 6480464 | Diethylhexyl Phthalate results in increased expression of HSDL2 mRNA | CTD | PMID:19850644 | bis(2-ethylhexyl) phthalate | multiple interactions | ISO | RGD:1551494 | 6480464 | PPARA protein promotes the reaction [Diethylhexyl Phthalate results in increased expression of HSDL2 mRNA] | CTD | PMID:19850644 | bisphenol A | decreases expression | ISO | RGD:1305387 | 6480464 | bisphenol A results in decreased expression of HSDL2 mRNA | CTD | PMID:25181051 | bisphenol A | affects expression | ISO | RGD:1305387 | 6480464 | bisphenol A affects the expression of HSDL2 mRNA | CTD | PMID:30903817 | bisphenol A | affects expression | EXP | | 6480464 | bisphenol A affects the expression of HSDL2 mRNA | CTD | PMID:30903817 | buspirone | increases expression | ISO | RGD:1305387 | 6480464 | Buspirone results in increased expression of HSDL2 mRNA | CTD | PMID:24136188 | cadmium atom | increases expression | EXP | | 6480464 | Cadmium results in increased expression of HSDL2 mRNA | CTD | PMID:24376830 | cisplatin | increases expression | ISO | RGD:1305387 | 6480464 | Cisplatin results in increased expression of HSDL2 mRNA | CTD | PMID:22023808 | cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin co-treated with jinfukang] results in increased expression of HSDL2 mRNA | CTD | PMID:27392435 | cisplatin | increases expression | EXP | | 6480464 | Cisplatin results in increased expression of HSDL2 mRNA | CTD | PMID:27392435, PMID:27594783 | clofibrate | affects expression | ISO | RGD:1305387 | 6480464 | Clofibrate affects the expression of HSDL2 mRNA | CTD | PMID:19483382 | clofibrate | increases expression | ISO | RGD:1551494 | 6480464 | Clofibrate results in increased expression of HSDL2 mRNA | CTD | PMID:17585979 more ... | clofibrate | multiple interactions | ISO | RGD:1551494 | 6480464 | [Clofibrate co-treated with Acetaminophen] affects the expression of HSDL2 mRNA, PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of HSDL2 mRNA] | CTD | PMID:17585979 | clofibrate | increases expression | ISO | RGD:1305387 | 6480464 | Clofibrate results in increased expression of HSDL2 protein | CTD | PMID:16470657 | cobalt dichloride | decreases expression | ISO | RGD:1305387 | 6480464 | cobaltous chloride results in decreased expression of HSDL2 mRNA | CTD | PMID:24386269 | copper(II) sulfate | decreases expression | EXP | | 6480464 | Copper Sulfate results in decreased expression of HSDL2 mRNA | CTD | PMID:19549813 | cyclosporin A | decreases expression | ISO | RGD:1551494 | 6480464 | Cyclosporine results in decreased expression of HSDL2 mRNA | CTD | PMID:19770486 | cyclosporin A | decreases expression | EXP | | 6480464 | Cyclosporine results in decreased expression of HSDL2 mRNA | CTD | PMID:20106945 more ... | decabromodiphenyl ether | increases expression | ISO | RGD:1305387 | 6480464 | decabromobiphenyl ether results in increased expression of HSDL2 mRNA | CTD | PMID:23640034 | decanoyl-CoA | multiple interactions | EXP | | 6480464 | [decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein | CTD | PMID:25526675 | dichloroacetic acid | increases expression | ISO | RGD:1551494 | 6480464 | Dichloroacetic Acid results in increased expression of HSDL2 mRNA | CTD | PMID:28962523 | dicrotophos | decreases expression | EXP | | 6480464 | dicrotophos results in decreased expression of HSDL2 mRNA | CTD | PMID:28302478 | doxorubicin | affects response to substance | EXP | | 6480464 | HSDL2 protein affects the susceptibility to Doxorubicin | CTD | PMID:16217747 | doxorubicin | decreases expression | ISO | RGD:1551494 | 6480464 | Doxorubicin results in decreased expression of HSDL2 mRNA | CTD | PMID:26873546 | ethanol | affects expression | ISO | RGD:1551494 | 6480464 | Ethanol affects the expression of HSDL2 mRNA | CTD | PMID:30319688 | ethyl methanesulfonate | increases expression | EXP | | 6480464 | Ethyl Methanesulfonate results in increased expression of HSDL2 mRNA | CTD | PMID:23649840 | finasteride | increases expression | ISO | RGD:1305387 | 6480464 | Finasteride results in increased expression of HSDL2 mRNA | CTD | PMID:24136188 | formaldehyde | increases expression | EXP | | 6480464 | Formaldehyde results in increased expression of HSDL2 mRNA | CTD | PMID:23649840 | glafenine | decreases expression | ISO | RGD:1305387 | 6480464 | Glafenine results in decreased expression of HSDL2 mRNA | CTD | PMID:24136188 | GW 501516 | multiple interactions | EXP | | 6480464 | [GW 501516 binds to PPARD protein] which results in increased expression of HSDL2 mRNA | CTD | PMID:16197558 | hexadecanoic acid | multiple interactions | EXP | | 6480464 | [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of HSDL2 mRNA, [Palmitic Acid co-treated with Oleic Acid] results in increased expression of HSDL2 mRNA | CTD | PMID:30547786 | indole-3-methanol | multiple interactions | ISO | RGD:1305387 | 6480464 | [indole-3-carbinol co-treated with Diethylnitrosamine] results in increased expression of HSDL2 mRNA | CTD | PMID:22129741 | L-ethionine | affects expression | ISO | RGD:1305387 | 6480464 | Ethionine affects the expression of HSDL2 mRNA | CTD | PMID:19483382 | lauroyl-CoA | multiple interactions | EXP | | 6480464 | [lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein | CTD | PMID:25526675 | leflunomide | increases expression | ISO | RGD:1305387 | 6480464 | leflunomide results in increased expression of HSDL2 mRNA | CTD | PMID:24136188 | methyl methanesulfonate | increases expression | EXP | | 6480464 | Methyl Methanesulfonate results in increased expression of HSDL2 mRNA | CTD | PMID:23649840 | N-nitrosodiethylamine | multiple interactions | ISO | RGD:1305387 | 6480464 | [indole-3-carbinol co-treated with Diethylnitrosamine] results in increased expression of HSDL2 mRNA | CTD | PMID:22129741 | NADP zwitterion | multiple interactions | EXP | | 6480464 | [22-hydroxycholesterol co-treated with NADP] binds to HSDL2 protein more ... | CTD | PMID:25526675 | NADP(+) | multiple interactions | EXP | | 6480464 | [22-hydroxycholesterol co-treated with NADP] binds to HSDL2 protein more ... | CTD | PMID:25526675 | nefazodone | increases expression | ISO | RGD:1305387 | 6480464 | nefazodone results in increased expression of HSDL2 mRNA | CTD | PMID:24136188 | nimesulide | increases expression | ISO | RGD:1305387 | 6480464 | nimesulide results in increased expression of HSDL2 mRNA | CTD | PMID:24136188 | oleic acid | multiple interactions | EXP | | 6480464 | [Palmitic Acid co-treated with Oleic Acid co-treated with TNF protein] affects the expression of HSDL2 mRNA, [Palmitic Acid co-treated with Oleic Acid] results in increased expression of HSDL2 mRNA | CTD | PMID:30547786 | omeprazole | affects expression | ISO | RGD:1305387 | 6480464 | Omeprazole affects the expression of HSDL2 mRNA | CTD | PMID:19483382 | oxybenzone | decreases expression | ISO | RGD:1305387 | 6480464 | oxybenzone results in decreased expression of HSDL2 mRNA | CTD | PMID:30316929 | paracetamol | multiple interactions | ISO | RGD:1551494 | 6480464 | [Clofibrate co-treated with Acetaminophen] affects the expression of HSDL2 mRNA, PPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of HSDL2 mRNA] | CTD | PMID:17585979 | paracetamol | affects expression | EXP | | 6480464 | Acetaminophen affects the expression of HSDL2 mRNA | CTD | PMID:25704631 | pentachlorophenol | increases expression | ISO | RGD:1551494 | 6480464 | Pentachlorophenol results in increased expression of HSDL2 mRNA | CTD | PMID:23892564 | perfluorohexanesulfonic acid | increases expression | ISO | RGD:1551494 | 6480464 | perfluorohexanesulfonic acid results in increased expression of HSDL2 mRNA | CTD | PMID:28558994 | perfluorononanoic acid | increases expression | ISO | RGD:1551494 | 6480464 | perfluorononanoic acid results in increased expression of HSDL2 mRNA | CTD | PMID:28558994 | perfluorooctane-1-sulfonic acid | increases expression | ISO | RGD:1551494 | 6480464 | perfluorooctane sulfonic acid results in increased expression of HSDL2 mRNA | CTD | PMID:28558994 | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | RGD:1551494 | 6480464 | PPARA protein affects the reaction [perfluorooctane sulfonic acid results in increased expression of HSDL2 mRNA] | CTD | PMID:28558994 | perfluorooctanoic acid | increases expression | ISO | RGD:1551494 | 6480464 | perfluorooctanoic acid results in increased expression of HSDL2 mRNA | CTD | PMID:28558994, PMID:30711707 | perfluorooctanoic acid | increases expression | ISO | RGD:1305387 | 6480464 | perfluorooctanoic acid results in increased expression of HSDL2 mRNA | CTD | PMID:28511854 | permethrin | increases expression | ISO | RGD:1551494 | 6480464 | Permethrin results in increased expression of HSDL2 mRNA | CTD | PMID:30629241 | pirinixic acid | affects expression | ISO | RGD:1305387 | 6480464 | pirinixic acid affects the expression of HSDL2 mRNA | CTD | PMID:19483382 | pirinixic acid | increases expression | ISO | RGD:1551494 | 6480464 | pirinixic acid results in increased expression of HSDL2 mRNA | CTD | PMID:17426115 more ... | potassium chromate | decreases expression | EXP | | 6480464 | potassium chromate(VI) results in decreased expression of HSDL2 mRNA | CTD | PMID:22079256 | potassium chromate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of HSDL2 mRNA | CTD | PMID:22079256 | pravastatin | decreases expression | ISO | RGD:1551494 | 6480464 | Pravastatin results in decreased expression of HSDL2 mRNA | CTD | PMID:27225895 | pravastatin | increases expression | ISO | RGD:1305387 | 6480464 | Pravastatin results in increased expression of HSDL2 mRNA | CTD | PMID:27225895 | rotenone | increases expression | ISO | RGD:1305387 | 6480464 | Rotenone results in increased expression of HSDL2 mRNA | CTD | PMID:28374803 | tacrolimus hydrate | decreases expression | ISO | RGD:1551494 | 6480464 | Tacrolimus results in decreased expression of HSDL2 mRNA | CTD | PMID:25270620 | Tesaglitazar | increases expression | ISO | RGD:1305387 | 6480464 | tesaglitazar results in increased expression of HSDL2 mRNA | CTD | PMID:21515302 | tetrachloromethane | decreases expression | ISO | RGD:1305387 | 6480464 | Carbon Tetrachloride results in decreased expression of HSDL2 mRNA | CTD | PMID:31150632 | tetrachloromethane | multiple interactions | ISO | RGD:1305387 | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of HSDL2 mRNA] | CTD | PMID:31150632 | thioacetamide | affects expression | ISO | RGD:1305387 | 6480464 | Thioacetamide affects the expression of HSDL2 mRNA | CTD | PMID:19483382 | tolcapone | increases expression | ISO | RGD:1305387 | 6480464 | tolcapone results in increased expression of HSDL2 mRNA | CTD | PMID:24136188 | trichloroethene | increases expression | ISO | RGD:1551494 | 6480464 | Trichloroethylene results in increased expression of HSDL2 mRNA | CTD | PMID:28973375 | trichostatin A | increases expression | EXP | | 6480464 | trichostatin A results in increased expression of HSDL2 mRNA | CTD | PMID:24935251 | trichostatin A | affects expression | EXP | | 6480464 | trichostatin A affects the expression of HSDL2 mRNA | CTD | PMID:28542535 | troglitazone | increases expression | ISO | RGD:1305387 | 6480464 | troglitazone results in increased expression of HSDL2 mRNA, troglitazone results in increased expression of HSDL2 protein | CTD | PMID:21315101, PMID:21515302 | valdecoxib | increases expression | ISO | RGD:1305387 | 6480464 | valdecoxib results in increased expression of HSDL2 mRNA | CTD | PMID:24136188 | valproic acid | affects expression | ISO | RGD:1551494 | 6480464 | Valproic Acid affects the expression of HSDL2 mRNA | CTD | PMID:17292431 | valproic acid | increases expression | EXP | | 6480464 | Valproic Acid results in increased expression of HSDL2 mRNA | CTD | PMID:23179753 more ... | valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of HSDL2 mRNA | CTD | PMID:25979313 | valproic acid | decreases expression | ISO | RGD:1551494 | 6480464 | Valproic Acid results in decreased expression of HSDL2 mRNA | CTD | PMID:21427059 | valproic acid | increases expression | ISO | RGD:1551494 | 6480464 | Valproic Acid results in increased expression of HSDL2 mRNA | CTD | PMID:21427059 | valproic acid | decreases expression | EXP | | 6480464 | Valproic Acid results in decreased expression of HSDL2 mRNA | CTD | PMID:23527032 | vinclozolin | affects expression | ISO | RGD:1305387 | 6480464 | vinclozolin affects the expression of HSDL2 mRNA | CTD | PMID:19015723 | zaragozic acid A | increases expression | ISO | RGD:1305387 | 6480464 | squalestatin 1 results in increased expression of HSDL2 mRNA | CTD | PMID:27225895 | zaragozic acid A | increases expression | ISO | RGD:1551494 | 6480464 | squalestatin 1 results in increased expression of HSDL2 mRNA | CTD | PMID:27225895 | |
|
|
|
|
|
|
|
|
|
1. | GOA_HUMAN data from the GO Consortium |
2. | RGD automated import pipeline for gene-chemical interactions |
PubMed | 8125298 12477932 12834046 14702039 16344560 16501878 18369455 19027726 19490893 19703561 19946888 20583170 20877624 22002062 22082156 22268729 23798571 24244333 26344197 26496610 26638075 26972000 27173435 27499296 27658777 27880917 28514442 28515276 29111377 29128334 29229926 29509190 29568061 29576527 29894468 30194290 30378028 30463901 |
HSDL2 (Homo sapiens - human) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hsdl2 (Mus musculus - house mouse) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hsdl2 (Rattus norvegicus - Norway rat) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hsdl2 (Chinchilla lanigera - long-tailed chinchilla) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HSDL2 (Pan paniscus - bonobo/pygmy chimpanzee) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HSDL2 (Canis lupus familiaris - dog) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Hsdl2 (Ictidomys tridecemlineatus - thirteen-lined ground squirrel) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HSDL2 (Sus scrofa - pig) |
|
D9S996E |
|
|||||||||||||||||||||||||||||||||||||||||||||
D9S2084 |
|
|||||||||||||||||||||||||||||||||||||||||||||
RH45928 |
|
|||||||||||||||||||||||||||||||||||||||||||||
SHGC-58384 |
|
|||||||||||||||||||||||||||||||||||||||||||||
A004Y48 |
|
The detailed report is available here: | ![]() | Full Report | ![]() | CSV | ![]() | TAB | ![]() | Printer |
miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/). For more information about miRGate, see PMID:25858286 or access the full paper here. |
RefSeq Transcripts | NM_001195822 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles |
NM_032303 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
NR_036651 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
XM_011519091 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
XM_017015203 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
XM_017015204 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
XM_017015205 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
GenBank Nucleotide | AK090940 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles |
AK098721 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
AK225946 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
AK289929 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
AK292486 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
AK301469 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
AK303645 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
AK313605 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
AL162732 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
AL833735 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
AY093428 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
BC004331 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
BC036620 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
BC047074 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
BC095451 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
CH471105 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
DB052480 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
HH961796 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles | |
KF458939 | (Get FASTA) | NCBI Sequence Viewer | Search GEO for Microarray Profiles |
RefSeq Acc Id: | NM_001195822 ⟹ NP_001182751 | ||||||||||||||||||||||||
RefSeq Status: | VALIDATED | ||||||||||||||||||||||||
Type: | CODING | ||||||||||||||||||||||||
Position: |
|
||||||||||||||||||||||||
Sequence: |
AAAGCGCCTGCGCGGAGAGCCTGCAATCAGGGACCAGGCTTGGGAGGCGACGAAGAGGAACGCThide sequence |
RefSeq Acc Id: | NM_032303 ⟹ NP_115679 | ||||||||||||||||||||||||||||||||||
RefSeq Status: | VALIDATED | ||||||||||||||||||||||||||||||||||
Type: | CODING | ||||||||||||||||||||||||||||||||||
Position: |
|
||||||||||||||||||||||||||||||||||
Sequence: |
AAAGCGCCTGCGCGGAGAGCCTGCAATCAGGGACCAGGCTTGGGAGGCGACGAAGAGGAACGCThide sequence |
RefSeq Acc Id: | NR_036651 | ||||||||||||||||||||||||
RefSeq Status: | VALIDATED | ||||||||||||||||||||||||
Type: | NON-CODING | ||||||||||||||||||||||||
Position: |
|
||||||||||||||||||||||||
Sequence: |
AAAGCGCCTGCGCGGAGAGCCTGCAATCAGGGACCAGGCTTGGGAGGCGACGAAGAGGAACGCThide sequence |
RefSeq Acc Id: | XM_011519091 ⟹ XP_011517393 | |||||||||
RefSeq Status: | ||||||||||
Type: | CODING | |||||||||
Position: |
|
|||||||||
Sequence: |
GGGGGGGCAGGGGCGGGGCAGGGGCGGGGATAAATGCGGAGGGACGGTCCAGCTTTAGCTCTCThide sequence |
RefSeq Acc Id: | XM_017015203 ⟹ XP_016870692 | |||||||||
RefSeq Status: | ||||||||||
Type: | CODING | |||||||||
Position: |
|
|||||||||
Sequence: |
GGTCCAGCTTTAGCTCTCTGCTCGCCGCCGCCGCTGTCGCCGCCACCTCCTCTGATCTACGAAAhide sequence |
RefSeq Acc Id: | XM_017015204 ⟹ XP_016870693 | |||||||||
RefSeq Status: | ||||||||||
Type: | CODING | |||||||||
Position: |
|
|||||||||
Sequence: |
GGGCAGGGGCGGGGATAAATGCGGAGGGACGGTCCAGCTTTAGCTCTCTGCTCGCCGCCGCCGChide sequence |
RefSeq Acc Id: | XM_017015205 ⟹ XP_016870694 | |||||||||
RefSeq Status: | ||||||||||
Type: | CODING | |||||||||
Position: |
|
|||||||||
Sequence: |
GGGGATAAATGCGGAGGGACGGTCCAGCTTTAGCTCTCTGCTCGCCGCCGCCGCTGTCGCCGCChide sequence |
Protein RefSeqs | NP_001182751 | (Get FASTA) | NCBI Sequence Viewer |
NP_115679 | (Get FASTA) | NCBI Sequence Viewer | |
XP_011517393 | (Get FASTA) | NCBI Sequence Viewer | |
XP_016870692 | (Get FASTA) | NCBI Sequence Viewer | |
XP_016870693 | (Get FASTA) | NCBI Sequence Viewer | |
XP_016870694 | (Get FASTA) | NCBI Sequence Viewer | |
GenBank Protein | AAH04331 | (Get FASTA) | NCBI Sequence Viewer |
AAH95451 | (Get FASTA) | NCBI Sequence Viewer | |
AAM14670 | (Get FASTA) | NCBI Sequence Viewer | |
BAF82618 | (Get FASTA) | NCBI Sequence Viewer | |
BAF85175 | (Get FASTA) | NCBI Sequence Viewer | |
BAG36370 | (Get FASTA) | NCBI Sequence Viewer | |
BAG62989 | (Get FASTA) | NCBI Sequence Viewer | |
BAG64648 | (Get FASTA) | NCBI Sequence Viewer | |
CAH56256 | (Get FASTA) | NCBI Sequence Viewer | |
CBX51371 | (Get FASTA) | NCBI Sequence Viewer | |
EAW59104 | (Get FASTA) | NCBI Sequence Viewer | |
EAW59105 | (Get FASTA) | NCBI Sequence Viewer | |
EAW59106 | (Get FASTA) | NCBI Sequence Viewer | |
EAW59107 | (Get FASTA) | NCBI Sequence Viewer | |
Q6YN16 | (Get FASTA) | NCBI Sequence Viewer |
RefSeq Acc Id: | NP_115679 ⟸ NM_032303 |
- Peptide Label: | isoform 1 |
- UniProtKB: | Q6YN16 (UniProtKB/Swiss-Prot) |
- Sequence: |
MLPNTGRLAGCTVFITGASRGIGKAIALKAAKDGANIVIAAKTAQPHPKLLGTIYTAAEEIEAVhide sequence |
RefSeq Acc Id: | NP_001182751 ⟸ NM_001195822 |
- Peptide Label: | isoform 2 |
- UniProtKB: | Q6YN16 (UniProtKB/Swiss-Prot), A0A024R159 (UniProtKB/TrEMBL) |
- Sequence: |
MLPNTGRLAGCTVFITGASRGIGKAIALKAAKDGANIVIAAKTAQPHPKLLGTIYTAAEEIEAVhide sequence |
RefSeq Acc Id: | XP_011517393 ⟸ XM_011519091 |
- Peptide Label: | isoform X1 |
- Sequence: |
MLPNTGRLAGCTVFITGASRGIGKAIALKAAKDGANIVIAAKTAQPHPKLLGTIYTAAEEIEAVhide sequence |
RefSeq Acc Id: | XP_016870693 ⟸ XM_017015204 |
- Peptide Label: | isoform X2 |
- Sequence: |
MSMYVLGMAEEFKGEIAVNALWPKTAIHTAAMDMLGGPGIESQCRKVDIIADAAYSIFQKPKSFhide sequence |
RefSeq Acc Id: | XP_016870694 ⟸ XM_017015205 |
- Peptide Label: | isoform X2 |
- Sequence: |
MSMYVLGMAEEFKGEIAVNALWPKTAIHTAAMDMLGGPGIESQCRKVDIIADAAYSIFQKPKSFhide sequence |
RefSeq Acc Id: | XP_016870692 ⟸ XM_017015203 |
- Peptide Label: | isoform X2 |
- Sequence: |
MSMYVLGMAEEFKGEIAVNALWPKTAIHTAAMDMLGGPGIESQCRKVDIIADAAYSIFQKPKSFhide sequence |
RGD ID: | 7215891 | |||||||||
Promoter ID: | EPDNEW_H13690 | |||||||||
Type: | initiation region | |||||||||
Name: | HSDL2_1 | |||||||||
Description: | hydroxysteroid dehydrogenase like 2 | |||||||||
SO ACC ID: | SO:0000170 | |||||||||
Source: | EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/) | |||||||||
Experiment Methods: | Single-end sequencing. | |||||||||
Position: |
|
RGD ID: | 6807296 | |||||||||
Promoter ID: | HG_KWN:64556 | |||||||||
Type: | CpG-Island | |||||||||
SO ACC ID: | SO:0000170 | |||||||||
Source: | MPROMDB | |||||||||
Tissues & Cell Lines: | CD4+TCell, CD4+TCell_12Hour, CD4+TCell_2Hour, HeLa_S3, Jurkat, K562, Lymphoblastoid, NB4 | |||||||||
Transcripts: | ENST00000398805, OTTHUMT00000053683, OTTHUMT00000053684, UC004BGB.1, UC004BGC.1 | |||||||||
Position: |
|
Name | Type | Condition(s) | Position(s) | Clinical significance |
GRCh38/hg38 9q22.33-33.1(chr9:99138048-115011033)x1 | copy number loss | Abnormal facial shape [RCV000050315]|See cases [RCV000050315] | Chr9:99138048..115011033 [GRCh38] Chr9:101900330..117773312 [GRCh37] Chr9:100940151..116813133 [NCBI36] Chr9:9q22.33-33.1 |
pathogenic |
GRCh38/hg38 9p24.3-q34.3(chr9:193412-138179445)x3 | copy number gain | Global developmental delay [RCV000050347]|Developmental Delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000050348]|Developmental delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000050348]|See cases [RCV000050348] | Chr9:193412..138179445 [GRCh38] Chr9:204193..141073897 [GRCh37] Chr9:194193..140193718 [NCBI36] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh38/hg38 9q22.33-33.1(chr9:99349916-115767475)x1 | copy number loss | Chiari malformation type II [RCV000052921]|See cases [RCV000052921] | Chr9:99349916..115767475 [GRCh38] Chr9:102112198..118529754 [GRCh37] Chr9:101152019..117569575 [NCBI36] Chr9:9q22.33-33.1 |
pathogenic |
GRCh38/hg38 9p24.3-q34.3(chr9:193412-138114463)x3 | copy number gain | Developmental Delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000053746]|Developmental delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000053746]|See cases [RCV000053746] | Chr9:193412..138114463 [GRCh38] Chr9:214367..141008915 [GRCh37] Chr9:204367..140128736 [NCBI36] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh38/hg38 9p24.3-q34.3(chr9:193412-138179445)x3 | copy number gain | Developmental Delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000053748]|Developmental delay and additional significant developmental and morphological phenotypes referred for genetic testing [RCV000053748]|See cases [RCV000053748] | Chr9:193412..138179445 [GRCh38] Chr9:266045..141073897 [GRCh37] Chr9:256045..140193718 [NCBI36] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh38/hg38 9p24.3-q34.3(chr9:193412-138124532)x3 | copy number gain | Intrauterine growth retardation [RCV000053745]|See cases [RCV000053745] | Chr9:193412..138124532 [GRCh38] Chr9:204193..141018984 [GRCh37] Chr9:194193..140138805 [NCBI36] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh38/hg38 9q22.1-32(chr9:88522292-113687796)x3 | copy number gain | Global developmental delay [RCV000053752]|See cases [RCV000053752] | Chr9:88522292..113687796 [GRCh38] Chr9:91137207..116450076 [GRCh37] Chr9:90327027..115489897 [NCBI36] Chr9:9q22.1-32 |
pathogenic |
GRCh38/hg38 9p24.3-q34.3(chr9:204193-138179445) | copy number gain | See cases [RCV000133791] | Chr9:204193..138179445 [GRCh38] Chr9:204193..141073897 [GRCh37] Chr9:194193..140193718 [NCBI36] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh38/hg38 9q31.1-32(chr9:103767420-112984794)x1 | copy number loss | See cases [RCV000134976] | Chr9:103767420..112984794 [GRCh38] Chr9:106529701..115747074 [GRCh37] Chr9:105569522..114786895 [NCBI36] Chr9:9q31.1-32 |
pathogenic |
GRCh38/hg38 9p24.3-q34.3(chr9:193412-138124524)x3 | copy number gain | See cases [RCV000138783] | Chr9:193412..138124524 [GRCh38] Chr9:204090..141018976 [GRCh37] Chr9:194090..140138797 [NCBI36] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh38/hg38 9p24.3-q34.3(chr9:193412-138159073)x3 | copy number gain | See cases [RCV000138962] | Chr9:193412..138159073 [GRCh38] Chr9:204104..141053525 [GRCh37] Chr9:194104..140173346 [NCBI36] Chr9:9p24.3-q34.3 |
pathogenic|conflicting data from submitters |
GRCh38/hg38 9p11.2-q34.3(chr9:193412-138159073)x3 | copy number gain | See cases [RCV000139207] | Chr9:193412..138159073 [GRCh38] Chr9:68420641..141053525 [GRCh37] Chr9:67910461..140173346 [NCBI36] Chr9:9p11.2-q34.3 |
pathogenic |
GRCh38/hg38 9q31.2-33.1(chr9:107530314-117965944)x1 | copy number loss | See cases [RCV000140794] | Chr9:107530314..117965944 [GRCh38] Chr9:110292595..120728222 [GRCh37] Chr9:109332416..119768043 [NCBI36] Chr9:9q31.2-33.1 |
pathogenic |
GRCh38/hg38 9p24.3-q34.3(chr9:203861-138125937)x3 | copy number gain | See cases [RCV000141876] | Chr9:203861..138125937 [GRCh38] Chr9:203861..141020389 [GRCh37] Chr9:193861..140140210 [NCBI36] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh38/hg38 9p24.3-q34.3(chr9:203862-138125937)x3 | copy number gain | See cases [RCV000143476] | Chr9:203862..138125937 [GRCh38] Chr9:203862..141020389 [GRCh37] Chr9:193862..140140210 [NCBI36] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh38/hg38 9q22.33-33.1(chr9:99138048-115011033)x1 | copy number loss | See cases [RCV000148264] | Chr9:99138048..115011033 [GRCh38] Chr9:101900330..117773312 [GRCh37] Chr9:100940151..116813133 [NCBI36] Chr9:9q22.33-33.1 |
pathogenic |
GRCh38/hg38 9p24.3-q34.3(chr9:193412-138179445)x3 | copy number gain | See cases [RCV000148113] | Chr9:193412..138179445 [GRCh38] Chr9:204193..141073897 [GRCh37] Chr9:194193..140193718 [NCBI36] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh37/hg19 9p24.3-q34.3(chr9:163131-141122114)x3 | copy number gain | See cases [RCV000240081] | Chr9:163131..141122114 [GRCh37] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh37/hg19 9p24.3-q34.3(chr9:62525-141006407) | copy number gain | See cases [RCV000449375] | Chr9:62525..141006407 [GRCh37] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh37/hg19 9q31.3-33.1(chr9:111348809-118687200)x1 | copy number loss | See cases [RCV000449308] | Chr9:111348809..118687200 [GRCh37] Chr9:9q31.3-33.1 |
pathogenic |
GRCh37/hg19 9p24.3-q34.3(chr9:203861-141020389)x3 | copy number gain | See cases [RCV000447207] | Chr9:203861..141020389 [GRCh37] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh37/hg19 9q31.1-33.3(chr9:104604851-126253089)x1 | copy number loss | See cases [RCV000447763] | Chr9:104604851..126253089 [GRCh37] Chr9:9q31.1-33.3 |
pathogenic |
GRCh37/hg19 9p24.3-q34.3(chr9:203864-141020389)x3 | copy number gain | See cases [RCV000448978] | Chr9:203864..141020389 [GRCh37] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh37/hg19 9q31.3-33.2(chr9:114299780-123267736)x1 | copy number loss | See cases [RCV000511049] | Chr9:114299780..123267736 [GRCh37] Chr9:9q31.3-33.2 |
pathogenic |
GRCh37/hg19 9q21.11-34.3(chr9:71069743-140999928) | copy number gain | Global developmental delay [RCV000626548]|Seizures [RCV000626548] | Chr9:71069743..140999928 [GRCh37] Chr9:9q21.11-34.3 |
likely pathogenic |
GRCh37/hg19 9p24.3-q34.3(chr9:203862-141020389) | copy number gain | See cases [RCV000512392] | Chr9:203862..141020389 [GRCh37] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh37/hg19 9q31.2-32(chr9:108664157-115356416)x3 | copy number gain | not provided [RCV000683161] | Chr9:108664157..115356416 [GRCh37] Chr9:9q31.2-32 |
likely pathogenic |
GRCh37/hg19 9q31.3-32(chr9:114726761-115498466)x3 | copy number gain | not provided [RCV000683145] | Chr9:114726761..115498466 [GRCh37] Chr9:9q31.3-32 |
uncertain significance |
GRCh37/hg19 9q31.3-33.3(chr9:113083182-126779494)x1 | copy number loss | not provided [RCV000748606] | Chr9:113083182..126779494 [GRCh37] Chr9:9q31.3-33.3 |
pathogenic |
GRCh37/hg19 9p24.3-q34.3(chr9:10590-141122247)x3 | copy number gain | not provided [RCV000748055] | Chr9:10590..141122247 [GRCh37] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh37/hg19 9p24.3-q34.3(chr9:10590-141107672)x3 | copy number gain | not provided [RCV000748053] | Chr9:10590..141107672 [GRCh37] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh37/hg19 9p24.3-q34.3(chr9:46587-141066491)x3 | copy number gain | not provided [RCV000748063] | Chr9:46587..141066491 [GRCh37] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh37/hg19 9p24.3-q34.3(chr9:10590-141114095)x2 | copy number gain | not provided [RCV000748054] | Chr9:10590..141114095 [GRCh37] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh37/hg19 9p24.3-q34.3(chr9:203861-141020388)x3 | copy number gain | not provided [RCV000845900] | Chr9:203861..141020388 [GRCh37] Chr9:9p24.3-q34.3 |
pathogenic |
GRCh37/hg19 9q31.3-32(chr9:113982711-117443628)x1 | copy number loss | not provided [RCV000847543] | Chr9:113982711..117443628 [GRCh37] Chr9:9q31.3-32 |
uncertain significance |
GRCh37/hg19 9q21.11-34.3(chr9:71416475-141020389)x3 | copy number gain | not provided [RCV000847808] | Chr9:71416475..141020389 [GRCh37] Chr9:9q21.11-34.3 |
pathogenic |
Database | Acc Id | Source(s) |
AGR Gene | HGNC:18572 | AgrOrtholog |
COSMIC | HSDL2 | COSMIC |
Ensembl Genes | ENSG00000119471 | ENTREZGENE, UniProtKB/Swiss-Prot |
Ensembl Protein | ENSP00000381783 | ENTREZGENE, UniProtKB/Swiss-Prot |
ENSP00000381785 | ENTREZGENE, UniProtKB/Swiss-Prot | |
Ensembl Transcript | ENST00000398803 | ENTREZGENE, UniProtKB/Swiss-Prot |
ENST00000398805 | ENTREZGENE, UniProtKB/Swiss-Prot | |
Gene3D-CATH | 3.30.1050.10 | UniProtKB/Swiss-Prot |
GTEx | ENSG00000119471 | GTEx |
HGNC ID | HGNC:18572 | ENTREZGENE |
Human Proteome Map | HSDL2 | Human Proteome Map |
InterPro | NAD(P)-bd_dom_sf | UniProtKB/Swiss-Prot |
Sc_DH/Rdtase_CS | UniProtKB/Swiss-Prot | |
SCP2_sterol-bd_dom | UniProtKB/Swiss-Prot | |
SCP2_sterol-bd_dom_sf | UniProtKB/Swiss-Prot | |
SDR_fam | UniProtKB/Swiss-Prot | |
KEGG Report | hsa:84263 | UniProtKB/Swiss-Prot |
NCBI Gene | 84263 | ENTREZGENE |
Pfam | adh_short | UniProtKB/Swiss-Prot |
SCP2 | UniProtKB/Swiss-Prot | |
PharmGKB | PA134980105 | PharmGKB |
PRINTS | GDHRDH | UniProtKB/Swiss-Prot |
PROSITE | ADH_SHORT | UniProtKB/Swiss-Prot |
Superfamily-SCOP | SSF51735 | UniProtKB/Swiss-Prot |
SSF55718 | UniProtKB/Swiss-Prot | |
UniGene | Hs.59486 | ENTREZGENE |
UniProt | A0A024R159 | ENTREZGENE, UniProtKB/TrEMBL |
HSDL2_HUMAN | UniProtKB/Swiss-Prot, ENTREZGENE | |
UniProt Secondary | A8K1L4 | UniProtKB/Swiss-Prot |
A8K8X1 | UniProtKB/Swiss-Prot | |
A8MSV3 | UniProtKB/Swiss-Prot | |
Q658M8 | UniProtKB/Swiss-Prot | |
Q9BT58 | UniProtKB/Swiss-Prot |
![]() |
More on HSDL2 | |
![]() |
Alliance Gene |
![]() |
NCBI Gene |
![]() |
Ensembl Gene |
![]() |
JBrowse: hg19 hg38 |
![]() |
HGNC Report |
![]() |
NCBI Genome Data Viewer |
CRRD Object Information | |
CRRD ID: | 1350650 |
Created: | 2005-03-08 |
Species: | Homo sapiens |
Last Modified: | 2019-11-26 |
Status: | ACTIVE |
![]() |
![]() |
![]() |
![]() |
RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.